A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid
leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety
and tolerability of the drug.